Medeon Biodesign (ROCO:6499) Cyclically Adjusted Revenue per Share: NT$4.19 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6499 Medeon Biodesign Inc ROCO:6499
63 GF Score
Price NT$57.10
GF Value NT$106.76
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Medeon Biodesign Cyclically Adjusted Revenue per Share?

Medeon Biodesign ROCO:6499 +2.33% 63 Cyclically Adjusted Revenue per Share is NT$4.19 as of Mar. 2026. GuruFocus rates ROCO:6499 with a GF Score™ of 63/100 and a GF Value™ of NT$106.76 (Possible Value Trap). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Medeon Biodesign's adjusted revenue per share for the three months ended in Mar. 2026 was NT$1.179. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$4.19 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Medeon Biodesign's average Cyclically Adjusted Revenue Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-02), Medeon Biodesign's current stock price is NT$57.10. Medeon Biodesign's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$4.19. Medeon Biodesign's Cyclically Adjusted PS Ratio of today is 13.63.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medeon Biodesign was 33.41. The lowest was 9.48. And the median was 12.10.


Medeon Biodesign  (ROCO:6499) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medeon Biodesign's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=57.10/4.19
=13.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Medeon Biodesign was 33.41. The lowest was 9.48. And the median was 12.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Medeon Biodesign Cyclically Adjusted Revenue per Share Related Terms


Medeon Biodesign Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Medeon Biodesign's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medeon Biodesign Cyclically Adjusted Revenue per Share Chart

Medeon Biodesign Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 3.93 3.94 4.10

Medeon Biodesign Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.06 4.08 4.10 4.19

ROCO:6499 vs ISRG, BDX, MDLN: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medeon Biodesign Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medeon Biodesign's Cyclically Adjusted PS Ratio falls into.


ROCO:6499
63GF Score
Medeon Biodesign Inc ROCO:6499
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medeon Biodesign Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medeon Biodesign's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.179/330.2130*330.2130
=1.179

Current CPI (Mar. 2026) = 330.2130.

Medeon Biodesign Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.371 241.432 0.507
201703 0.463 243.801 0.627
201706 0.684 244.955 0.922
201709 0.344 246.819 0.460
201712 0.588 246.524 0.788
201803 5.789 249.554 7.660
201806 0.691 251.989 0.906
201809 0.793 252.439 1.037
201812 0.993 251.233 1.305
201903 1.051 254.202 1.365
201906 1.199 256.143 1.546
201909 1.346 256.759 1.731
201912 1.310 256.974 1.683
202003 1.472 258.115 1.883
202006 0.153 257.797 0.196
202009 0.097 260.280 0.123
202012 0.899 260.474 1.140
202103 0.118 264.877 0.147
202106 0.415 271.696 0.504
202109 0.105 274.310 0.126
202112 0.106 278.802 0.126
202203 2.038 287.504 2.341
202206 0.316 296.311 0.352
202209 0.449 296.808 0.500
202212 0.347 296.797 0.386
202303 0.466 301.836 0.510
202306 0.556 305.109 0.602
202309 0.493 307.789 0.529
202312 0.597 306.746 0.643
202403 0.507 312.332 0.536
202406 0.684 314.175 0.719
202409 1.126 315.301 1.179
202412 0.865 315.605 0.905
202503 1.095 319.799 1.131
202506 1.184 322.561 1.212
202509 0.993 324.800 1.010
202512 1.276 324.054 1.300
202603 1.179 330.213 1.179

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$4.19 mean?
Medeon Biodesign (ROCO:6499) has a Cyclically Adjusted Revenue per Share of NT$4.19 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medeon Biodesign and its competitors.
Is Medeon Biodesign's Cyclically Adjusted Revenue per Share too high?
Medeon Biodesign's current Cyclically Adjusted Revenue per Share is NT$4.19. Overall, Medeon Biodesign has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's Cyclically Adjusted Revenue per Share compare to ISRG and BDX?
Medeon Biodesign's Cyclically Adjusted Revenue per Share of NT$4.19 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Medeon Biodesign and its competitors. Medeon Biodesign's current Cyclically Adjusted Revenue per Share is NT$4.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Possible Value Trap. The stock's GF Value™ is NT$106.76, compared to a current price of NT$57.10 — trading 46.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$4.19. Medeon Biodesign's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current Cyclically Adjusted Revenue per Share is NT$4.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?

Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued. The current stock price of NT$57.10 is trading 46.5% below its estimated GF Value™ of NT$106.76. GuruFocus considers Medeon Biodesign to be Possible Value Trap.

Key valuation signals for ROCO:6499:

  • Cyclically Adjusted Revenue per Share: NT$4.19
  • GF Value™: NT$106.76 vs. price of NT$57.10 (46.5% below fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medeon Biodesign Business Description

Address No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
63GF Score

Get the complete analysis for ROCO:6499

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$57.10
Price
NT$106.76
GF Value